Health Trials

EGFR-mutated NSCLC

2

Review clinical trials related to EGFR-mutated NSCLC. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Participants needed: 76
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: ORIC PharmaceuticalsUpdated: Apr 24, 2026Locations: 4
Eligibility criteria

Histologically or cytologically confirmed metastatic NSCLC with a documented EGF... [+7]

Known small cell lung cancer transformation [+5]

Read more
Status: Recruiting

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Gruppo Oncologico Italiano di Ricerca ClinicaUpdated: Apr 22, 2026Locations: 25
Eligibility criteria

Age ≥ 18 years [+5]

Unavailability of tissue and/or liquid biopsy sample collected at the time of re... [+2]

Read more